Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer

Oncogene volume 35, pages 4807–4815 (2016)Cite this article

Subjects

Abstract

Androgen receptor (AR)-mediated gene expression continues to have a critical role in promoting castration-resistant prostate cancer (CRPC) survival and growth even after androgen deprivation therapy. AR cistrome analyses in CRPC cells have identified a large number of AR target genes involved in proliferative and cell cycle-related functions, and hold promise for development of novel therapeutic approaches for CRPC. However, there is little understanding of how these genes function in vivo and what the clinical implications are. We previously reported that secretory leukocyte peptidase inhibitor (SLPI) is regulated by the AR in a ligand-independent manner in CRPC cells and required for CRPC cell proliferation under androgen-deprived conditions. SLPI is a secreted serine protease inhibitor, which is overexpressed in a number of cancers, including lung, breast and ovarian cancer, and involved in tumor progression. However, the oncogenic potential of SLPI in prostate cancer remains unknown. Here we provide the first evidence that SLPI is upregulated in a subset of CRPC cell lines and CRPC patient tumors. In addition, serum SLPI levels are significantly elevated in metastatic CRPC patients compared with hormone naive patients, raising the possibility that this could serve as a biomarker. We demonstrated that SLPI expression has functional significance, as it promotes CRPC cell survival and growth after androgen withdrawal in vivo and in vitro. Last, we demonstrated that the oncogenic effect of SLPI may be due to protection of growth factor progranulin from enzymatic cleavage or suppression of CRPC cell apoptosis independent of anti-protease activity of SLPI. These findings implicate SLPI as a potential biomarker of resistance to AR inhibition and therapeutic target for CRPC treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. American Cancer Society Cancer Facts & Figures 2015. American Cancer Society: Atlanta, GA, USA, 2015.

  2. Bernard B, Sweeney CJ . Management of metastatic hormone-sensitive prostate cancer. Curr Urol Rep 2015; 16: 14.

    Article  PubMed  Google Scholar 

  3. Shen MM, Abate-Shen C . Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24: 1967–2000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Karantanos T, Corn PG, Thompson TC . Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013; 32: 5501–5511.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187–1197.

    Article  CAS  PubMed  Google Scholar 

  7. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138–148.

    Article  CAS  PubMed  Google Scholar 

  8. Decker KF, Zheng D, He Y, Bowman T, Edwards JR, Jia L . Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res 2012; 40: 10765–10779.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM . Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7: 167–174.

    Article  CAS  PubMed  Google Scholar 

  10. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000; 6: 1833–1839.

    CAS  PubMed  Google Scholar 

  11. Nukiwa T, Suzuki T, Fukuhara T, Kikuchi T . Secretory leukocyte peptidase inhibitor and lung cancer. Cancer Sci 2008; 99: 849–855.

    Article  CAS  PubMed  Google Scholar 

  12. Cheng WL, Wang CS, Huang YH, Liang Y, Lin PY, Hsueh C et al. Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer. Int J Cancer 2008; 123: 1787–1796.

    Article  CAS  PubMed  Google Scholar 

  13. Hoskins E, Rodriguez-Canales J, Hewitt SM, Elmasri W, Han J, Han S et al. Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells. Gynecol Oncol 2011; 122: 656–662.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kluger HM, Chelouche Lev D, Kluger Y, McCarthy MM, Kiriakova G, Camp RL et al. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res 2005; 65: 5578–5587.

    Article  CAS  PubMed  Google Scholar 

  15. Lowe AW, Olsen M, Hao Y, Lee SP, Taek Lee K, Chen X et al. Gene expression patterns in pancreatic tumors, cells and tissues. PLoS ONE 2007; 2: e323.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Devoogdt N, Rasool N, Hoskins E, Simpkins F, Tchabo N, Kohn EC . Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. Cancer Sci 2009; 100: 434–440.

    Article  CAS  PubMed  Google Scholar 

  17. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H . Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 2003; 100: 5778–5782.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kluger HM, Kluger Y, Gilmore-Hebert M, DiVito K, Chang JT, Rodov S et al. cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest 2004; 84: 320–331.

    Article  CAS  PubMed  Google Scholar 

  19. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992; 90: 1296–1301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Song X, Zeng L, Jin W, Thompson J, Mizel DE, Lei K et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 1999; 190: 535–542.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lentsch AB, Yoshidome H, Warner RL, Ward PA, Edwards MJ . Secretory leukocyte protease inhibitor in mice regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion. Gastroenterology 1999; 117: 953–961.

    Article  CAS  PubMed  Google Scholar 

  22. Gipson TS, Bless NM, Shanley TP, Crouch LD, Bleavins MR, Younkin EM et al. Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. J Immunol 1999; 162: 3653–3662.

    CAS  PubMed  Google Scholar 

  23. Simpkins FA, Devoogdt NM, Rasool N, Tchabo NE, Alejandro EU, Kamrava MM et al. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis 2008; 29: 466–472.

    Article  CAS  PubMed  Google Scholar 

  24. Rasool N, LaRochelle W, Zhong H, Ara G, Cohen J, Kohn EC . Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells. Clin Cancer Res 2010; 16: 600–609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Thompson M, Lapointe J, Choi YL, Ong DE, Higgins JP, Brooks JD et al. Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle. Prostate 2008; 68: 1248–1256.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54: 2577–2581.

    CAS  PubMed  Google Scholar 

  27. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8: 393–406.

    Article  CAS  PubMed  Google Scholar 

  28. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7: 64.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002; 111: 867–878.

    Article  CAS  PubMed  Google Scholar 

  30. Huang, da W, Sherman BT, Lempicki RA . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44–57.

    Article  CAS  Google Scholar 

  31. Lee EC, Zhan P, Schallhom R, Packman K, Tenniswood M . Antiandrogen-induced cell death in LNCaP human prostate cancer cells. Cell Death Differ 2003; 10: 761–771.

    Article  CAS  PubMed  Google Scholar 

  32. Chopra DP, Menard RE, Januszewski J, Mattingly RR . TNF-alpha-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett 2004; 203: 145–154.

    Article  CAS  PubMed  Google Scholar 

  33. Wang D, Montgomery RB, Schmidt LJ, Mostaghel EA, Huang H, Nelson PS et al. Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res 2009; 69: 9448–9456.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Davis JS, Nastiuk KL, Krolewski JJ . TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable. Mol Endocrinol 2011; 25: 611–620.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ameshima S, Ishizaki T, Demura Y, Imamura Y, Miyamori I, Mitsuhashi H . Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma. Cancer 2000; 89: 1448–1456.

    Article  CAS  PubMed  Google Scholar 

  36. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K . Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 2005; 96: 516–519.

    Article  CAS  PubMed  Google Scholar 

  37. Johnsen M, Lund LR, Romer J, Almholt K, Dano K . Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998; 10: 667–671.

    Article  CAS  PubMed  Google Scholar 

  38. Liotta LA, Kohn EC . The microenvironment of the tumour-host interface. Nature 2001; 411: 375–379.

    Article  CAS  PubMed  Google Scholar 

  39. Higashiyama M, Doi O, Yokouchi H, Kodama K, Nakamori S, Tateishi R . Alpha-1-antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression. Cancer 1995; 76: 1368–1376.

    Article  CAS  PubMed  Google Scholar 

  40. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513–2521.

    CAS  PubMed  Google Scholar 

  41. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000; 60: 6281–6287.

    CAS  PubMed  Google Scholar 

  42. Zelvyte I, Wallmark A, Piitulainen E, Westin U, Janciauskiene S . Increased plasma levels of serine proteinase inhibitors in lung cancer patients. Anticancer Res 2004; 24: 241–247.

    CAS  PubMed  Google Scholar 

  43. Kataoka H, Itoh H, Koono M . Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration. Pathol Int 2002; 52: 89–102.

    Article  CAS  PubMed  Google Scholar 

  44. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008; 13: 519–528.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L et al. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res 2014; 20: 4904–4911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Wagenblast E, Soto M, Gutierrez-Angel S, Hartl CA, Gable AL, Maceli AR et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature 2015; 520: 358–362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. He Z, Ong CH, Halper J, Bateman A . Progranulin is a mediator of the wound response. Nat Med 2003; 9: 225–229.

    Article  CAS  PubMed  Google Scholar 

  48. He Z, Bateman A . Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl) 2003; 81: 600–612.

    Article  CAS  Google Scholar 

  49. Monami G, Emiliozzi V, Bitto A, Lovat F, Xu SQ, Goldoni S et al. Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. Am J Pathol 2009; 174: 1037–1047.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L et al. PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin Cancer Res 2004; 10: 1333–1337.

    Article  CAS  PubMed  Google Scholar 

  51. Tangkeangsirisin W, Hayashi J, Serrero G . PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Res 2004; 64: 1737–1743.

    Article  CAS  PubMed  Google Scholar 

  52. Lovat F, Bitto A, Xu SQ, Fassan M, Goldoni S, Metalli D et al. Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis 2009; 30: 861–868.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, Wong SY et al. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008; 47: 1524–1532.

    Article  CAS  PubMed  Google Scholar 

  54. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202: 1659–1668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Jan Treda C, Fukuhara T, Suzuki T, Nakamura A, Zaini J, Kikuchi T et al. Secretory leukocyte protease inhibitor modulates urethane-induced lung carcinogenesis. Carcinogenesis 2014; 35: 896–904.

    Article  PubMed  Google Scholar 

  56. Jia L, Shen HC, Wantroba M, Khalid O, Liang G, Wang Q et al. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol 2006; 26: 7331–7341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Zheng D, Decker KF, Zhou T, Chen J, Qi Z, Jacobs K et al. Role of WNT7B-induced noncanonical pathway in advanced prostate cancer. Mol Cancer Res 2013; 11: 482–493.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 2010; 68: 654–667.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Smyth GK . Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: 1–25.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by Anthony DiNovi Fund. Ilker Tinay was partially supported by the ‘Turkiye Kanserle Savas Vakfi’ Scholarship Program.

Author information

Authors and Affiliations

  1. Department of Medicine, Center for Pharmacogenomics, Washington University School of Medicine, St Louis, MO, USA

    D Zheng & Q Huang

  2. Division of Urology, Department of Surgery, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

    B Gui, I Tinay, S Rafiei, A S Kibel & L Jia

  3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA, USA

    K P Gray

  4. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

    C J Sweeney

Authors
  1. D Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Gui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K P Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Tinay
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Rafiei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Q Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C J Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A S Kibel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Jia.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zheng, D., Gui, B., Gray, K. et al. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene 35, 4807–4815 (2016). https://doi.org/10.1038/onc.2016.13

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2016.13

This article is cited by

Search

Advanced search

Quick links